¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"relative hearing"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • relative risk ratio
    »ó´ëÀ§Çèºñ
  • relative scotoma
    »ó´ë¾ÏÁ¡
  • relative sterility
    »ó´ëÀûºÒÀÓ
  • relative survival rate
    »ó´ë»ýÁ¸À²
  • relative valvular insufficiency
    »ó´ëÀûÆÇ¸·±â´ÉºÎÀü
  • resource based relative value scale
    ÀÚ¿ø±âÁØ»ó´ë°¡Ä¡µî±Þ
  • audiometric hearing loss
    û·Â¼Ò½Ç
  • air conduction hearing
    °ø±âÀüµµµè±â, °ø±âÀüµµÃ»·Â
  • absolute hearing
    Àý´ëÀ½°¨
  • binaural hearing
    ¾çÂʱ͵è±â, ¾çÀÌû
  • bone conduction hearing
    »ÀÀüµµµè±â, °ñÀüµµÃ»·Â
  • conductive hearing loss
    ÀüÀ½³­Ã», Àüµµ³­Ã»
  • congenital hereditary hearing loss
    ¼±ÃµÀ¯Àü³­Ã»
  • central hearing loss
    ÁßÃßû·Â¼Ò½Ç, ÁßÃß³­Ã»
  • double disharmonic hearing
    ÀÌÁßµè±â, º¹Ã»
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • relative odds
    »ó´ëÀû´ëÀÀºñ
  • relative magnetic permeability
    »ó´ëÀÚ±âÅõ°ú·Â
  • relative refractory period
    »ó´ëºÒÀÀ±â
  • relative
    °ü°è
  • relative risk
    ºñ±³À§Çèµµ
  • relative scotoma
    »ó´ë¾ÏÁ¡
  • relative sterility
    »ó´ëÀûºÒÀÓ(Áõ)
  • relative biologic biologic effectiveness radiation
    »ó´ë»ý¹°ÇÐÀûÈ¿°ú
  • relative metabolic rate
    »ó´ë´ë»çÀ²
  • relative osteoid volume
    »ó´ëÀ¯°ñ·®
  • relative survival rate
    »ó´ë»ýÁ¸À²
  • resource based relative value scale
    Áö¿ø±âÁØ»ó´ë°¡Ä¡
  • absolute hearing
    Àý´ëÀ½°¨
  • air conduction hearing
    °ø±âÀü´Þµè±â, ±âµµÃ»·Â
  • audiometric hearing loss
    û·Â¼Ò½Ç
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • relative centrifugal force
    »ó´ë¿ø½É·Â(ßÓÓßêÀãýæ³).
  • relative convergence
    »ó´ëÆøÁÖ(ÝïÎòÜßñÍ), »ó´ë´«¸ðÀ½
  • relative dispersion
    »ó´ëºÐ»ê(ßÓÓßÝÂߤ).
  • relative divergence
    ºñ±³°³»ê(ÝïÎòËÒߤ).
  • relative dose
    ºñ±³ Á¶»ç·®
  • relative dullness
    °æÅ¹À½°è(ÌîöúëåÍ£).
  • relative dullness
    °æÅ¹À½°è(ÌîöúëåÍ£)
  • relative error
    »ó´ë¿ÀÂ÷(Ë×ËÀËí̤).
  • relative field
    ºñ±³¿µ¿ª(ÝïÎòçÐæ´).
  • relative flatness
    »ó´ëŹÀ½
  • relative frequency
    ºñ±³ºóµµ(ËÓË´Ë×̬).
  • relative growth
    »ó´ëÀû »ýÀå(ßÓÓßîÜßæíþ)
  • relative hepatic dullness
    »ó´ë°£Å¹À½°è(ßÓÓßÊÜöúëåÍ£).
  • relative hepatic dullness
    »ó´ë°£Å¹À½°è(ßÓÓßÊÜöúëåÍ£)
  • relative humidity
    »ó´ë½Àµµ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • relative centrifugal force
    »ó´ë¿ø½É·Â(ßÓÓßêÀãýæ³).
  • relative centrifugal force
    ºñ¿ø½É·Â.
  • relative convergence
    »ó´ëÆøÁÖ(ÝïÎòÜßñÍ), »ó´ë´«¸ðÀ½
  • relative dispersion
    »ó´ëºÐ»ê(ßÓÓßÝÂߤ).
  • relative divergence
    ºñ±³°³»ê(ÝïÎòËÒߤ).
  • relative dose
    ºñ±³ Á¶»ç·®
  • relative dullness
    °æÅ¹À½°è(ÌîöúëåÍ£).
  • relative dullness
    °æÅ¹À½°è(ÌîöúëåÍ£)
  • relative error
    »ó´ë¿ÀÂ÷(Ë×ËÀËí̤).
  • relative field
    ºñ±³¿µ¿ª(ÝïÎòçÐæ´).
  • relative flatness
    »ó´ëŹÀ½
  • relative frequency
    ºñ±³ºóµµ(ËÓË´Ë×̬).
  • relative growth
    »ó´ëÀû »ýÀå(ßÓÓßîÜßæíþ)
  • relative hepatic dullness
    »ó´ë°£Å¹À½°è(ßÓÓßÊÜöúëåÍ£).
  • relative hepatic dullness
    »ó´ë°£Å¹À½°è(ßÓÓßÊÜöúëåÍ£)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
HD   1) Hodgkin's Disease
  2) Hemo-Dialysis
  3) High Density
&...
AHRF acute hypoxemic respiratory failure; American Hearing Research Foundation
AHS Academy of Health Sciences; African horse sickness; alveolar hypoventilation syndrome; American Hear...
ASHA American School Health Association; American Social Health Association; American Speech and Hearing ...
BTE behind the ear [hearing aid]; bovine thymus extract
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
HI Hearing impairment
H.L. Hearing level
HL Hearing loss
HTL Hearing threshold level
NIHL Noise Induced Hearing Loss
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 7 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • hearing defect
    û·Â Àå¾Ö
    ºÎºÐÀûÀ¸·Î ȤÀº ¿ÏÀüÈ÷ µé¸®Áö ¾Ê´Â °Í.
  • hearing disturbance
    û·Â Àå¾Ö
    À½À» Á¦´ë·Î ´À³¢Áö ¸øÇÏ´Â »óÅÂ.
  • hearing organ
    û°¢ ±â°ü
    À½À» ´À³¢´Âµ¥ »ç¿ëµÇ´Â ±â°üÀ¸·Î external acoustic meatus¸¦ ºñ·ÔÇÏ¿© ear drum µîÀ» Æ÷ÇÔÇÑ´Ù.
  • monaural hearing
    ÀÏÀÌ Ã»°¢
  • sensorineural hearing loss
    °¨°¢ ½Å°æ¼º ³­Ã»
  • sensory hearing loss
    °¨°¢¼º ³­Ã»
    ¿Í¿ì
  • speech hearing test
    ¾îÀ½ û·Â °Ë»ç
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
relative scotoma A scotoma in which there is visual depression but not complete loss of light perception.
(05 Mar 2000)
relative sensitivity The sensitivity of a medical screening test as determined by comparison with the same type of test; e.g., sensitivity of a new serological test relative to sensitivity of an established serological test.
(05 Mar 2000)
relative specificity The specificity of a medical screening test as determined by comparison with the same type of test (e.g., specificity of a new serological test relative to specificity of an established serological test).
(05 Mar 2000)
relative value scales Coded listings of physician or other professional services using units that indicate the relative value of the various services they perform. They take into account time, skill, and overhead cost required for each service, but generally do not consider the relative cost-effectiveness. Appropriate conversion factors can be used to translate the abstract units of the relative value scales into dollar fees for each service based on work expended, practice costs, and training costs.
(12 Dec 1998)
relative viscosity The ratio of the viscosity of a solution or dispersion to the viscosity of the solvent or continuous phase.
(05 Mar 2000)
5-year relative survival rate <statistics> The likelihood that a patient will not die from causes associated with his or her cancer for at least 5 years after diagnosis. This is the standard many professionals use when determining someone a survivor of cancer.
(16 Dec 1997)
american speech-language-hearing association A professional society concerned with the diagnosis, prevention, treatment, and remediation of speech, language, and hearing disorders.
(12 Dec 1998)
rehabilitation of hearing impaired Procedures for assisting a person with a hearing disorder to maximum comprehension in communication.
(12 Dec 1998)
resonance theory of hearing That the basilar membrane of the cochlea acts as a resonating structure, recording low tones from its apical turns and high tones from its basal turns.
Synonym: Helmholtz theory of hearing.
(05 Mar 2000)
Weber's test for hearing The application of a vibrating tuning fork to one of several points in the midline of the head or face, to ascertain in which ear the sound is heard best by bone conduction, that ear being the affected one if the sound-conducting apparatus (middle ear) is at fault (positive test), but probably the normal one if the neurosensory apparatus is diseased (negative test).
(05 Mar 2000)
conductive hearing loss <otolaryngology> A form of deafness that results from a blockage of the ear canal or dysfunction of the ossicles or eardrum (sound collecting apparatus).
In conductive hearing loss the auditory nerve is normal, but there exists a physical problem with the sound collecting apparatus.
(05 Jan 1998)
hearing The sensation of sound.
(12 Dec 1998)
hearing aid An electronic amplifying device designed to bring sound more effectively into the ear; it consists of a microphone, amplifier, and receiver.
(05 Mar 2000)
hearing aids Devices which amplify sound to help persons with hearing loss.
(12 Dec 1998)
hearing impaired persons Persons with any degree of loss of hearing that has an impact on their activities of daily living or that requires special assistance or intervention.
(12 Dec 1998)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 1 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • relative pronoun
    °ü°è ´ë¸í»ç
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
ÅëÇÕ°Ë»ö ¿Ï·á